Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Begins Japan Trials Of Mood, Anxiety Drugs From Denmark

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceuticals says it has begun trials of the first of two drugs licensed from H. Lundbeck of Denmark to treat mood and anxiety disorders. As LuAA21004, the first of the two drugs, enters trials, Takeda plans to develop LuAA24530. The drugs have differing molecular structures and are intended to be sold along side each other. Both drugs are well into Phase II trials in Europe. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts